India and Pfizer at impasse over vaccine indemnity demand -sources
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SUNDAY, MAY 29, 2022
SUNDAY, MAY 29, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
India and Pfizer at impasse over vaccine indemnity demand -sources

Coronavirus chronicle

Reuters
21 May, 2021, 05:15 pm
Last modified: 21 May, 2021, 05:18 pm

Related News

  • Pfizer says 3 Covid shots protect children under 5
  • Cash-rich Pfizer to pay $11.6 bln for Biohaven in biggest deal since 2016
  • EU regulator backs using Pfizer Covid shot as booster after other vaccines
  • Demand for Pfizer's Covid pills lags around the world
  • Pfizer eyes Covid vaccine for all variants before 2023

India and Pfizer at impasse over vaccine indemnity demand -sources

India has not given any manufacturer of a Covid-19 vaccine indemnity against the costs of compensation for any severe side effects, which is a condition Pfizer has obtained in many countries where its shots have already been widely rolled out, including Britain and the United States

Reuters
21 May, 2021, 05:15 pm
Last modified: 21 May, 2021, 05:18 pm
A medical worker administers a dose of the "Comirnaty" Pfizer-BioNTech COVID-19 vaccine in a vaccination center in Paris as part of the coronavirus disease (COVID-19) vaccination campaign in France, May 12, 2021. REUTERS/Gonzalo Fuentes/File Photo
A medical worker administers a dose of the "Comirnaty" Pfizer-BioNTech COVID-19 vaccine in a vaccination center in Paris as part of the coronavirus disease (COVID-19) vaccination campaign in France, May 12, 2021. REUTERS/Gonzalo Fuentes/File Photo

Pfizer (PFE.N) and the Indian government are at loggerheads over a demand by the U.S. drugmaker for legal protection from any claims linked to the use of its COVID-19 vaccine in one of the world's biggest markets, two sources told Reuters.

India has not given any manufacturer of a Covid-19 vaccine indemnity against the costs of compensation for any severe side effects, which is a condition Pfizer has obtained in many countries where its shots have already been widely rolled out, including Britain and the United States.

"The whole problem with Pfizer is the indemnity bond. Why should we sign it?" an Indian government source with direct knowledge of the matter told Reuters.

"If something happens, a patient dies, we will not be able to question them (Pfizer). If somebody challenges in a court of law, the central government will be responsible for everything, not the company," the source added.

Pfizer and India's health ministry did not reply to Reuters requests for comment on Friday.

The second source said Pfizer was not going to change its position on the indemnity issue.

Both sources declined to be named as they were not authorised to talk to the media.

Local Trail 

India, which is facing a shortage of shots as coronavirus cases soar, pledged last month to fast-track approvals for overseas vaccine makers including Pfizer, Moderna (MRNA.O) and Johnson and Johnson (JNJ.N).

However, none have since sought permission from India's drug regulator to sell their vaccine in the country, which has a population of 1.35 billion. read more

The second source said that the other issue being discussed between Pfizer and New Delhi was the Indian government's insistence on a local trial for any vaccine approval.

Pfizer withdrew its application for emergency use authorisation for the vaccine developed with Germany's BioNTech in February after India insisted on such a trial.

But three other shots on sale in India, developed by AstraZeneca (AZN.L), Russia's Sputnik V and Bharat Biotech in collaboration with state-run Indian Council of Medical Research, have completed the small-scale safety trials.

Albert Bourla, Pfizer's chief executive said on May 4 that he was hopeful that the government would change its policy of local trials and that a path to delivering the drugmaker's shots in India could be found.

A third source told Reuters that India's foreign minister would visit the United States this month or in early June to try and address Pfizer's concerns and ease exports of vaccine raw materials to India.

The Indian foreign ministry did not immediately respond to a request for comment.

Top News / World+Biz

Covid-19 pandemic / Pfizer

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Finance projects export fall, remittance rise
    Finance projects export fall, remittance rise
  • Photo: TBS
    After 72-hour ultimatum, health directorate goes after illegal medical facilities 
  • Photo: Bloomberg
    Direct shipping now to Netherlands 

MOST VIEWED

  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    'Tomorrow will be better': Shanghai inches towards Covid re-opening
  • North Korea says new fever cases under 100,000 as virus fight heats up
    North Korea says new fever cases under 100,000 as virus fight heats up
  • People in protective suits cross a street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    Shanghai heading out of lockdown but China still lost in economic gloom
  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Tightening Covid net, Beijing deals out punishments, stark warnings
  • A medical worker takes a swab sample from a person for a nucleic acid test at a makeshift testing site, amid the coronavirus disease (Covid-19) outbreak, in Beijing, China May 23, 2022. REUTERS/Tingshu Wang
    Beijing ramps up Covid quarantine, Shanghai residents decry uneven rules
  • A vial labelled with the Pfizer-BioNTech coronavirus disease (Covid-19) vaccine is seen in this illustration picture taken March 19, 2021. Photo :Reuters
    Pfizer says 3 Covid shots protect children under 5

Related News

  • Pfizer says 3 Covid shots protect children under 5
  • Cash-rich Pfizer to pay $11.6 bln for Biohaven in biggest deal since 2016
  • EU regulator backs using Pfizer Covid shot as booster after other vaccines
  • Demand for Pfizer's Covid pills lags around the world
  • Pfizer eyes Covid vaccine for all variants before 2023

Features

Women voluntarily joined the peaceful procession and protested by wearing clothing of their own choice. Photo: Trishia Nashtaran

The unhealthy obsession with what women wear

1h | Panorama
Illustration: Freepik

Bangladesh is on the verge of destigmatising menstruation

6h | Features
Photo: Collected

The death of Davos?

12h | Panorama
A male Baya Weaver beating wings. Photo: Enam Ul Haque

Baya Weavers weave: ‘Must be witnessed to be fully credited’

15h | Panorama

More Videos from TBS

Attorney General's suggestion to reduce case clutter

Attorney General's suggestion to reduce case clutter

6h | Videos
Russian forces take Liman city of Ukraine

Russian forces take Liman city of Ukraine

6h | Videos
JU food prices spike, students suffer

JU food prices spike, students suffer

6h | Videos
5% tax on poultry farmers earning above Tk10 lakh

5% tax on poultry farmers earning above Tk10 lakh

6h | Videos

Most Read

1
Bangladesh Bank GM, DGM’s designation changed
Banking

Bangladesh Bank GM, DGM’s designation changed

2
Corporates go cashless…tax cut on cards
NBR

Corporates go cashless…tax cut on cards

3
Photo: Courtesy
Panorama

Misfit Technologies: A Singaporean startup rooted firmly in Bangladesh

4
British International Investment (BII) CEO Nick O’Donohoe. Illustration: TBS
Economy

BII to invest $450m in Bangladesh in 5 years

5
Representational image. Picture: Pixabay
Economy

Govt raises regulatory duty to discourage imports of 130 products

6
Photo: Collected
Industry

Spanish recycled cotton producer opens new facility in Bangladesh

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab